Quality of integrated care for patients with nonsmall cell lung cancer

Abstract

Mammalian cells play a dominant role in the industrial production of biopharmaceutical proteins. However, the productivity of producer cells is often hindered by a bottleneck in the saturated secretory pathway, where a sophisticated mechanism of vesicle trafficking is mediated by numerous proteins and their complexes, among which are the cross‐kingdom conserved SNAREs [soluble NSF (N‐ethylmaleimide‐sensitive factor) receptor]. The SNAREs assemble into complexes by means of four interactive α‐helices and, thus, trigger the fusion of transport vesicles with the respective target membranes. We report that the transgenic expression of exocytic SNAREs, which control the fusion of secretory vesicles to the plasma membrane, differentially impacts the secretory capacity of HEK‐293, HeLa, and CHO‐K1 cells. While other exocytic SNAREs have no effect or a negative effect, SNAP‐23 [synaptosome‐associated protein of 23 kDa] and VAMP8 [vesicle‐associated membrane protein 8] specifically increase the production of recombinant proteins when they are ectopically and stably expressed in mammalian cells. The targeted and effective intervention in the secretory capacity of SNARE proteins is a novel engineering strategy, which could lead to the development of new therapies by increasing the production of biopharmaceutical proteins or by boosting the secretion of cell implants in cell therapy initiatives. Biotechnol. Bioeng. 2011; 108:611–620. © 2010 Wiley Periodicals, Inc.

Regional differences in treatment and outcome in non-small cell lung cancer: A population-based study (Sweden)

“…Our results are therefore important in that they call to improve the understanding of these factors. The data presented here do not only have a more limited meaning as an example of that the introduction of guidelines is not enough for good and equal quality; our findings seem to reflect an international phenomenon [26][27][28][29][30]. Thus, the underlying problems which our region will have to tackle, appear to be shared by providers of modern lung cancer care elsewhere.…”

Multidisciplinary team management in thoracic oncology: more than just a concept?

“…At least one institution in each of Norway, Italy, Finland and Romania reported that they did not discuss any of their patients at an MDT meeting [14]. Similar findings were reported in a Dutch review of care of patients with nonsmall cell lung cancer, which found that in 2004-2005 only two out of six hospitals in the eastern Netherlands had a MDT for lung cancer and the proportion of patients discussed varied between 26% and 91% [15].…”

Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations

“…A key barrier to implementing biomarker testing in metastatic NSCLC is ensuring adequate tissue acquisition and processing for molecular analyses.This acquisition involves a series of decisions that require coordinated efforts and communication across multiple health care disciplines ( Fig. 1) [4,7,19,20,22,23]. For this reason, a series of three multidisciplinary advisory boards were convened with clinicians from academic institutions (n 5 5), community settings (n 5 5), and integrated health systems (n 5 3) to identify best practices in implementing evidence-based recommendations to guide biomarkerdriven therapies.…”